259 related articles for article (PubMed ID: 31995556)
1. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Huhn GD; Ramgopal M; Jain MK; Hinestrosa F; Asmuth DM; Slim J; Goldstein D; Applin S; Ryu JH; Jiang S; Cox S; Das M; Nguyen-Cleary T; Piontkowsky D; Guyer B; Rossaro L; Haubrich RH
PLoS One; 2020; 15(1):e0224875. PubMed ID: 31995556
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
Banga J; Nizami S; Slim J; Nagarakanti S; Portilla M; Swaminathan S
Medicine (Baltimore); 2020 Mar; 99(11):e19140. PubMed ID: 32176039
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
6. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Isakov V; Gankina N; Morozov V; Kersey K; Lu S; Osinusi A; Svarovskaia E; Brainard DM; Salupere R; Orlova-Morozova E; Zhdanov K
Clin Drug Investig; 2018 Mar; 38(3):239-247. PubMed ID: 29177645
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM;
HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737
[TBL] [Abstract][Full Text] [Related]
9. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
11. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
[TBL] [Abstract][Full Text] [Related]
12. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
14. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA; Kitrinos KM; Fordyce M; McCallister S; Miller MD; Callebaut C
HIV Clin Trials; 2016 Mar; 17(2):78-87. PubMed ID: 26892863
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
Del Rio-Valencia JC; Asensi-Diez R; Tamayo-Bermejo R; Muñoz-Castillo I
Rev Esp Quimioter; 2019 Aug; 32(4):296-302. PubMed ID: 31232572
[TBL] [Abstract][Full Text] [Related]
16. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Buggisch P; Vermehren J; Mauss S; Günther R; Schott E; Pathil A; Boeker K; Zimmermann T; Teuber G; Vornkahl HP; Simon KG; Niederau C; Wedemeyer H; Zeuzem S
J Hepatol; 2018 Apr; 68(4):663-671. PubMed ID: 29133244
[TBL] [Abstract][Full Text] [Related]
18. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
19. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
[No Abstract] [Full Text] [Related]
20. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
